Although the loss of the FGF2 receptor gene is associated with a poor prognosis in glioma patients [23], FGF2 seems to be persistently expressed because it has been identified as an oncogenic factor in GBM [24], and its expression has been confirmed in other gliomas and meningiomas [25]. Here, FGF2 is linked to central nervous system cancer.